Barclays Notes the Payoffs From The Aetna & Coventry Deal

Barclays’ research review of the recent acquisition of Coventry Health Care, Inc. (NYSE:CVH) by Aetna Inc. (NYSE:AET) is highly appreciative of the merger.

Though the stock rating for Aetna Inc. (NYSE:AET) is maintained unchanged at Overweight, and so is the Price Target at $55, it would be useful to look at the many factors that . . .


This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here

If you are subscribed and having an account error please clear cache and then cookies if that does not work email and we will get back to you as quick as humanly possible

Saved Articles

Are you a smart investor? Join tens of thousands of sophisticated investor reading our authoritative free newsletter

* indicates required

Congrats! Are you a smart person?

We have an exclusive targeted for being a sophisticated and loyal reader.

Sign up today and get three months free

Use coupon code 2019VIP or click on the button below

Limited time offer only expires 9/16/2019 or next 20 9 whichever comes first – please do not share this discount with others